[89zr]zr-crefmirlimab berdoxam
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Aug 31, 2024 (NCT06218069)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- T-cell surface glycoprotein CD8 alpha chainRadiopharmaceutical
CD8A radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 89-zirconium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06218069 | Phase 2/Phase 3 (Phase 3) | Aug 31, 2024 | ImaginAb, Inc., Pfizer, Radboud University, University of Tuebingen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImaginAb, Inc. | For profit | 1 | 0 | 1 | 2024 |
| Pfizer | For profit | 1 | 0 | 1 | 2024 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Tuebingen | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1